痴呆症预防计划 (pdp):卢森堡的一个全国性个性化预防计划
Valerie E Schröder1,2, Amna Skrozic1,2, Dorothee Erz1,2
1Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Journal of Alzheimer's disease : JAD
|January 8, 2024
概括
卢森堡的一项全国性痴呆症预防计划成功招募了参与者进行个性化的生活方式干预. 这证明了实施这种策略来延缓风险人群的认知衰退的可行性.
科学领域:
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
- 老年学是一门学科.
背景情况:
- 老龄化社会面临着越来越多的认知衰退和痴呆症,阿尔茨海默病是最常见的原因.
- 有效的痴呆症预防策略对于减轻神经退行性疾病的社会负担至关重要.
研究的目的:
- 概述卢森堡痴呆症预防计划 (pdp) 的方法论,并介绍卢森堡痴呆症预防计划的初步发现.
- 评估队列特征和个性化,多领域的生活方式干预措施的实施过程.
主要方法:
- 个性化评估,包括神经心理评估和每个参与者的风险因素分析.
- 根据个人评估结果,开发个性化的多领域生活方式干预措施.
主要成果:
- 选了450名参与者 (平均年龄69.5岁),其中425人 (94.4%) 符合选择标准.
- 建立了医疗保健提供者的网络,以便在全国范围内实施.
结论:
- 该研究为全国性痴呆症预防计划的可行性提供了证据.
- 通过一个协作医疗保健网络,成功招募了目标人群.
相关概念视频
Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115
Cognitive Development During Adulthood
112
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
112
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490


